Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Lymphoma 4Leukemia 4Lymphoma, Mantle-Cell 3Waldenstrom Macroglobulinemia 2Sarcoma 2Medulloblastoma 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Lymphocytic, Chronic, B-Cell 2Central Nervous System Neoplasms 2Sezary Syndrome 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleuropulmonary blastoma 1Osteosarcoma 1Neuroblastoma 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Kidney Neoplasms 1Hodgkin Disease 1Hepatoblastoma 1Familial ependymoma 1Congenital Abnormalities 1

Interventions

Rituximab 52Cyclophosphamide 42fludarabine phosphate 41Peripheral Blood Stem Cell Transplantation 41Whole-Body Irradiation 26Mycophenolic Acid 25Cyclosporine 21Bortezomib 21Dexamethasone 19Busulfan 18Tacrolimus 17Etoposide 17Filgrastim 15Antilymphocyte Serum 14Methotrexate 13Melphalan 13ibrutinib 12Radiotherapy 11Calcium Dobesilate 9Sirolimus 8Lenalidomide 8Cyclosporins 8Methylprednisolone 7Flow Cytometry 7Everolimus 7Carboplatin 7ibritumomab tiuxetan 6zanubrutinib 5fludarabine 5Transplantation 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Waldenstrom Macroglobulinemia × Gene Rearrangement × Clear all
NCT00546377 2016-05-12

Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
50 enrolled 7 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT00621452 2014-08-06

Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma

Fred Hutchinson Cancer Center

Phase 1 Completed
12 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡